Day One’s Ojemda Gets FDA Accelerated Approval for Pediatric Brain Tumor

Day One Biopharmaceuticals on Tuesday announced that it has secured the FDA’s accelerated approval for tovorafenib, which will be marketed under the brand name Ojemda, for the treatment of relapsed or refractory pediatric low-grade glioma in patients aged six months and older.